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Abstract Increasing heart workload stimulates glycolysis by
enhancing glucose transport and fructose-2,6-bisphosphate
(Fru-2,6-P2), the latter resulting from 6-phosphofructo-2-kinase
(PFK-2) activation. Here, we investigated whether adenosine
monophosphate (AMP)-activated protein kinase (AMPK) medi-
ates PFK-2 activation in hearts submitted to increased work-
load. When heart work was increased, PFK-2 activity, Fru-2,6-
P2 content and glycolysis increased, whereas the AMP:adeno-
sine triphosphate (ATP) and phosphocreatine/creatine (PCr:Cr)
ratios, and AMPK activity remained unchanged. Wortmannin,
the well-known phosphatidylinositol-3-kinase inhibitor, blocked
the activation of protein kinase B and the increase in glycolysis
and Fru-2,6-P2 content induced by increased work. Therefore,
the control of heart glycolysis by contraction di¡ers from that in
skeletal muscle where AMPK is involved.
- 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Increasing cardiac work stimulates glycolysis to cope with
the extra energy demand [1]. This adaptive response of the
heart involves an increase in glucose uptake and fructose-
2,6-bisphosphate (Fru-2,6-P2) content [2]. Fru-2,6-P2 is syn-
thesized by 6-phosphofructo-2-kinase (PFK-2) and stimulates
6-phosphofructo-1-kinase (PFK-1), a key enzyme of glycoly-
sis. Myocardial ischemia also stimulates glycolysis. The latter
is mediated by adenosine monophosphate (AMP)-activated
protein kinase (AMPK), which senses the energy charge of
the cell and is activated by an increase in the AMP:adenosine
triphosphate (ATP) ratio [3,4]. AMPK activates heart PFK-2
and so increases Fru-2,6-P2 concentration [3], and it stimu-
lates glucose transport through the translocation of GLUT-4
to the plasma membrane [5]. In skeletal muscle, AMPK acti-
vation is responsible for the stimulation of glycolysis which
results from either oxygen deprivation or muscle contraction,
both of which increase the AMP:ATP ratio [6,7]. In this tis-
sue, the extent of AMPK activation depends on the force of
contraction [8]. Therefore, AMPK involvement in the control
of glycolysis has been postulated to occur in hearts submitted
to increased workload [9]. Here, we tested this hypothesis and
we investigated the role of AMPK in the stimulation of gly-
colysis and more particularly in the activation of PFK-2 by
increased heart work in the isolated working heart. In this
model, contraction and the work produced by the heart
were modulated by changing the afterload. We showed that,
in contrast to skeletal muscle, AMPK was not activated by
increased heart work and that PFK-2 activation was pre-
vented by wortmannin, a well-known inhibitor of the phos-
phatidylinositol-3-kinase (PI3K)/protein kinase B (PKB/Akt)
axis.
2. Materials and methods
Hearts of fed male Wistar rats (250^300 g, anesthetized with 60 mg/
kg pentobarbital intraperitoneally) were ¢rst perfused retrogradely via
the aorta for 5 min at 75 cm H2O, while the left atrium was cannu-
lated. The hearts were then perfused in ‘working’ conditions as in [10],
at 37‡C in a recirculating system with 100 ml of a Krebs^Henseleit
bicarbonate bu¡er containing 5 mM glucose and 2.5 mM CaCl2, if
not otherwise stated, and in equilibrium with a gas phase containing
95% O2 and 5% CO2, except under hypoxic (95% dry air and 5%
CO2) or anoxic (95% N2 and 5% CO2) conditions. The perfusion
protocols are described in the legends to the ¢gures and table. Hearts
were freeze-clamped at the indicated times for measurement of metab-
olites or enzyme activities. The ‘low load’ and ‘high load’ conditions
corresponded to hearts perfused with an afterload of 60 and 120 cm
H2O respectively, the preload being 20 cm H2O in all conditions. In a
second set of experiments, hearts were perfused at 100 cm H2O and
then submitted to an acute increase in afterload up to 140 cm H2O.
Measurements of heart rate, peak systolic pressure, mean aortic blood
pressure (MABP), and aortic and coronary outputs and calculation of
heart work were as in [2]. Samples of the frozen left ventricules were
homogenized at 4‡C in 9 Vol of a lysis bu¡er [3]. AMPK [3], PKB
(immunoprecipitated with anti-PKBK from UBI) [11] and PFK-2 ac-
tivity [3], Fru-2,6-P2 [12], AMP, adenosine diphosphate (ADP), ATP
[13] and phosphocreatine (PCr) and creatine (Cr) content [14] were
measured as described. Acetyl-CoA carboxylase (ACC) phosphoryla-
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tion was evaluated by immunoblotting with anti-phosphoSer-79ACC
(generous gift from D.G. Hardie, Dundee), which recognizes the cog-
nate Ser-227 in ACC2 [15]. Glycolysis was estimated by the rate of
detritiation of [3-3H]glucose [16]. Proteins were measured by Coomas-
sie blue staining with bovine serum albumin as a standard. Except
otherwise stated, the values are meansOS.E.M., the statistical signi¢-
cance of di¡erences was calculated by the Student’s t-test.
3. Results
3.1. Increased heart work stimulates glycolysis without change
in AMPK activity
Hearts were perfused at ‘low load’ (60 cm H2O) and then
submitted to an acute increase in afterload (‘high load’, 120
Table 1
Hemodynamic parameters of working hearts submitted to an acute increase in afterload
Heart rate
(min31)
MABP
(mm Hg)
Coronary output
(ml/min)
Cardiac output
(ml/min)
Hydraulic power
(mW)
Without
DMSO
60 cm H2O 236O 10 51O 1 8.6O 0.8 28.4O 5.4 3.1 O 0.6
60C120 cm H2O, 1 min N.D. 99O 2* 23.4O 1.8* 45.8O 5.7* 9.8 O 1.3*
60C120 cm H2O, 15 min 237O 25 100O 1* 21.8O 2.6* 40.3O 4.2* 8.7 O 0.9*
DMSO 60 cm H2O 235O 27 54O 2 8.9O 0.8 32.0O 6.3 3.8 O 0.8
60C120 cm H2O, 15 min 246O 31 99O 2* 23.6O 0.7* 40.9O 4.2* 8.8 O 0.8*
WMN 60 cm H2O 218O 17 53O 2 9.7O 0.5 29.4O 4.7 3.5 O 1.3
60C120 cm H2O, 15 min 227O 31 93O 2* 21.6O 0.9* 31.8O 4.2 6.2 O 0.8*
Hearts were submitted to an acute increase in afterload (120 cm H2O) after a 15 min period of equilibration at 60 cm H2O. The hemodynamic
parameters were measured after 1 and 15 min of increased workload as indicated. Wortmannin (WMN), dissolved in dimethylsulfoxide
(DMSO), was added to the perfusion medium after 5 min of equilibration to reach a ¢nal concentration of 100 nM. The hearts were then sub-
mitted to an increase in afterload (from 60 cm H2O to 120 cm H2O) after 15 min of equilibration. The hemodynamic parameters were mea-
sured after 15 min of increased workload as indicated. DMSO was the vehicle. The values are the meansOS.E.M. of at least six hearts.
*P6 0.01 indicates values that are statistically di¡erent from the control hearts. N.D., non-determined.
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Fig. 1. E¡ect of acute increase in pressure load on PFK-2 (A) and AMPK (B) activity, Fru-2,6-P2 content (B), AMP/ATP (C) and PCr/Cr ra-
tio (D). Hearts were submitted to an acute increase in afterload (120 cm H2O) after a 15 min period of equilibration at 60 cm H2O. The hearts
were freeze-clamped at the indicated times for measurement of AMPK and PFK-2 activity, and Fru-2,6-P2, AMP, ATP, PCr and Cr content.
The ATP concentration was 2.66O 0.15 and 2.71O0.17 Wmol/g tissue, the PCr concentration was 3.15O 0.22 and 3.19O 0.2 Wmol/g tissue, at
‘low load’ and at 15 min ‘high load’, respectively. The values are the meansOS.E.M. for at least ¢ve hearts. *P6 0.05 indicates values that are
statistically di¡erent from control hearts.
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cm H2O). The acute change in load increased the work (Table
1) as well as PFK-2 activity and Fru-2,6-P2 concentration
(Fig. 1A, B). It also increased the £ux through PFK-1 mea-
sured by the rate of detritiation of [3-3H]glucose (‘low load’,
36O 4; ‘high load’, 53O 4 Wmol glucose h31 g tissue31, n=3,
P6 0.05). In contrast, AMPK remained remarkably constant
during this transition from ‘low to high load’ (Fig. 1B). Allo-
steric e¡ectors of AMPK [17] were also measured in these
hearts. No change in Cr, PCr and ATP were detected, whereas
a small decrease in AMP, and hence in the AMP:ATP ratio,
was detected at 1 min which became statistically signi¢cant at
15 min (Fig. 1C, D). These results rule out any activation or
allosteric stimulation of AMPK under these conditions.
In another series of experiments, hearts were equilibrated at
100 cm H2O for 15 min and then submitted to an acute in-
crease in afterload of 140 cm H2O for up to 10 min to mimic a
pressure overload. Again, this experimental protocol induced
an increase in Fru-2,6-P2 content (control, 28.7 O 2.6; 140 cm
H2O, 10 min, 38.1O 2.8 pmol/mg protein, n=4, P6 0.05) but
failed to activate AMPK at any time points (control, 109O 20;
140 cm H2O, 1 min, 74O 13; 140 cm H2O, 10 min, 118O 20
mU/mg protein, n=3, P is not signi¢cant). Increasing Ca2þ
concentration from 1.5 to 10 mM in the perfusion medium of
hearts equilibrated at 100 cm H2O, which is known to in-
crease the force of contraction [18], did not change AMPK
activity (data not shown).
Comparison of the e¡ects of oxygen restriction with those
of increased afterload showed that the increase in Fru-2,6-P2
content was similar in both conditions, whereas AMPK was
only activated in hypoxia or anoxia (Fig. 2A). Moreover, Ser-
227 phosphorylation in ACC2, a known substrate of AMPK
[19], increased only when the oxygen supply was restricted
(Fig. 2B). In conclusion, AMPK activation was not observed
when heart work was increased, whatever the time-course, the
mean aortic blood pressure or the Ca2þ concentration used in
the perfusate.
3.2. Wortmannin inhibits PFK-2 and PKB activation by
increased workload
Perfusing hearts with wortmannin, the well-known inhibitor
of PI3K, prevented both the increase in Fru-2,6-P2 content
and the stimulation of glycolysis resulting from the increased
workload (Fig. 3A and B). Wortmannin also decreased car-
diac output without changing the mean aortic blood pressure
and coronary £ow (Table 1); it had no e¡ect on AMPK
activity (data not shown). Therefore, PI3K appears to be in-
volved in the hemodynamic and metabolic adaptation of the
heart to an acute increase in pressure load.
PKB is activated by insulin in the heart in a wortmannin-
sensitive manner [20] and it is able to phosphorylate and ac-
tivate heart PFK-2 in vitro [21]. Perfusing hearts at high load
resulted in PKB activation, which was prevented by wortman-
nin (Fig. 3C). p70 ribosomal S6 kinase (p70S6K) is another
protein kinase that is activated by insulin in the heart by a
wortmannin-sensitive mechanism [22], and that is able to
phosphorylate and activate heart PFK-2 in vitro [21].
p70S6K activation involves several protein kinases, one of
which is the mammalian target of rapamycin, which is inhib-
ited by rapamycin [23]. A role for p70S6K in PFK-2 activa-
tion was ruled out since, by contrast with PKB, p70S6K ac-
tivity remained unchanged when the workload was increased
and since rapamycin had no e¡ect on Fru-2,6-P2 content after
the increase in pressure load (data not shown).
4. Discussion
Contraction leads to AMPK activation in isolated muscle
preparations as well as in vivo [24]. Our data demonstrate that
this does not hold true for the heart. Indeed increasing heart
work stimulated glycolysis but did not activate AMPK or
change the AMP:ATP or PCr:Cr ratios. However, AMPK
was activated after oxygen deprivation, indicating that
AMPK activation is restricted to stress conditions and that
the normoxic heart adapts its metabolism to the extra energy
demand without involving AMPK.
Both oxygen deprivation and increasing workload stimulate
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Fig. 2. E¡ect of hypoxia, anoxia and workload on Fru-2,6-P2 con-
tent (A), AMPK activity (B), and ACC phosphorylation state (C).
The hearts were perfused for 15 min at 60 cm H2O and then sub-
mitted to hypoxia or anoxia for 5 min. They were compared with
hearts submitted to an increase in afterload as in Fig. 1. The values
are the meansOS.E.M. for at least ¢ve hearts. *P6 0.05 indicates
values that are statistically di¡erent from control hearts. C: Phos-
phorylation state of Ser-227 in ACC2; 50 Wg of protein from heart
extracts were loaded on each lane for sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE). The blot shown is rep-
resentative of three experiments.
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heart glycolysis by enhancing glucose transport and by in-
creasing PFK-2 activity. However, the mechanisms involved
are di¡erent. AMPK mediates the e¡ects of anoxia. Our
present results show that PFK-2 activation by workload,
like the metabolic e¡ects of insulin, are wortmannin-sensitive.
The wortmannin-sensitive stimulation of cardiac glucose
transport during contraction has already been described in a
model of electrically stimulated cardiomyocytes [25]. In this
model, the stimulation of glucose transport could not be re-
lated to changes in activity or phosphorylation of the insulin
receptor, the insulin receptor substrate-1 or insulin receptor
substrate-1 associated PI3K, indicating that the upstream sig-
nalling di¡ers from that of insulin. In addition, the authors
failed to demonstrate any activation of protein kinases down-
stream of PI3K that could be involved in the stimulation of
glucose transport. In our model of isolated working heart, we
showed that PKB was activated by workload to an extent that
is similar to that observed in hearts perfused with 1 nM in-
sulin [11]. Therefore, PKB appears as a possible candidate to
mediate PFK-2 activation.
Wortmannin did not inhibit basal PFK-2 activity, as al-
ready reported [26], although it inhibited PKB. This suggests
that PFK-2 was not activated when hearts were perfused at
‘low load’ (subphysiological conditions). Indeed, PFK-2 activ-
ity as well as Fru-2,6-P2 content were close to those found in
non-working hearts in which no PFK-2 phosphorylation was
detected [3].
Our data do not allow us to exclude the involvement of
protein kinases other than PKB, downstream of PI3K, in
PFK-2 activation by workload. Activation of the PI3K/PKB
axis has been reported to occur in contracting skeletal muscle
[27] as well as in endothelial cells submitted to laminar shear
stress [28]. This suggests that mechanical forces could play a
role in the activation of the PI3K/PKB pathway in di¡erent
tissues. The mechano-transducer and the signalling pathway
linking this transducer to PI3K remain to be elucidated.
Wortmannin limits the work developed after an increase in
afterload. This could result from a decrease in energy supply,
as the workload-induced stimulation of glycolysis was inhib-
ited. Similarly, wortmannin treatment counteracts the positive
inotropic e¡ect of insulin in the post-ischemic heart [29].
However, the data do not allow one to exclude the possibility
that the activation of the PI3K/PKB pathway improves heart
function, independent of its metabolic e¡ects, by controlling
either excitation^contraction coupling and/or muscle contrac-
tion. The latter is supported by a recent work showing that
PI3K in£uences contraction of vascular smooth muscle cells
[30].
Our results suggest that the PI3K/PKB pathway could par-
ticipate in the adaptation of cardiac function to an increased
afterload. Moreover, PKB could mediate other e¡ects. In-
deed, overexpression of PKB induces a moderate cardiac hy-
pertrophy with preserved systolic function [31]. Thus, it is not
excluded that, in addition to its metabolic e¡ects, the PI3K/
PKB pathway could participate in the early events leading to
the adjustment of cardiac mass to hemodynamic load. In con-
trast, AMPK appears not to be involved in the genesis of
hypertrophy in response to acute pressure load as it has
been already suggested [32].
Acknowledgements: The assistance of L. Maisin and A. Delacauw is
gratefully acknowledged. We thank G. Van den Berghe, S. Horman
and N. Brady for their continuous interest. C.B. and A.-S.M are
supported by the Belgian Fund for Scienti¢c Research and L.B. by
the ‘Actions de Recherche concertees’ 98/03-216 (French Community
of Belgium). This work was supported by the Belgian Federal Pro-
gramme of Interuniversity Poles of Attraction (P5), by the Belgian
Fund for Medical Scienti¢c Research and by the European Pro-
gramme QLG1-CT-2001-01488 (AMPDIAMET).
References
[1] Opie, L.H., Mansford, K.R.L. and Owem, P. (1971) Biochem. J.
124, 475^490.
[2] Depre, C., Rider, M.H., Veitch, K. and Hue, L. (1993) J. Biol.
Chem. 268, 13274^13279.
[3] Marsin, A.-S., Bertrand, L., Rider, M.H., Deprez, J., Beauloye,
C., Vincent, M.-F., Van den Berghe, G., Carling, D. and Hue, L.
(2000) Curr. Biol. 10, 1247^1250.
[4] Hardie, D.G., Carling, D. and Carlson, M. (1998) Annu. Rev.
Biochem. 67, 821^855.
F
ru
-2
,6
-P
2
 (
p
m
o
l/
m
g
 p
ro
t)
WMN
high load 
+ + +
1 min 15 min
1 min 15 min
A
B
C
0
4
8
12
16
0
20
40
60
g
ly
c
o
ly
ti
c
 f
lu
x
 (
µ
m
o
l 
g
lu
c
o
s
e
/h
/g
 t
is
s
u
e
)
WMN
high load +
+ +
+
*
*
*
#
#
0
250
500
750
1000
1250
P
K
B
 a
c
ti
v
it
y
 (
µ
U
/m
g
 p
ro
t)
*
*
###
WMN
high load
+ + +
Fig. 3. E¡ect of wortmannin on Fru-2,6-P2 content (A), glycolytic
£ux (B) and PKB activity (C) in hearts submitted to an acute in-
crease in afterload. Wortmannin (WMN) was added to the perfu-
sion medium after 5 min of equilibration to reach a ¢nal concentra-
tion of 100 nM. The hearts were submitted to an increase in
afterload (from 60 cm H2O to 120 cm H2O) after 15 min of equili-
bration and freeze-clamped at 1 and 15 min under high load condi-
tion to measure Fru-2,6-P2 content (A) and PKB activity (C). The
values are the meansOS.E.M. for at least four hearts. *P6 0.05 in-
dicates values that are statistically di¡erent from the low load
hearts, equilibrated at 60 cm H2O. #P6 0.05 indicates values that
are statistically di¡erent from the corresponding untreated hearts.
FEBS 26698 23-10-02
C. Beauloye et al./FEBS Letters 531 (2002) 324^328 327
[5] Russell, R.R., Bergeron, R., Shulman, G.I. and Young, L.H.
(1999) Am. J. Physiol. 277, H643^H649.
[6] Mu, J., Brozinick, M.J., Valladares, O., Bucan, M. and Birn-
baum, M.J. (2001) Mol. Cell. 7, 1085^1094.
[7] Fryer, L.G.D., Foufelle, F., Barnes, K., Baldwin, S.A., Woods,
A. and Carling, D. (2002) Biochem. J. 363, 167^174.
[8] Ihleman, J., Ploug, T., Hellste, Y. and Galbo, H. (2000) Am. J.
Physiol. 279, E862^E867.
[9] Hardie, D.G. (2000) Curr. Biol. 10, R757^R759.
[10] Taegtmeyer, H., Hems, R. and Krebs, H.A. (1980) Biochem. J.
186, 701^711.
[11] Beauloye, C., Bertrand, L., Krause, U., Marsin, A.-S., Dresse-
laers, T., Vanstapel, F., Vanoverschelde, J.-L. and Hue, L. (2001)
Circ. Res. 88, 513^519.
[12] Van Schaftingen, E., Lederer, B., Bartrons, R. and Hers, H.G.
(1982) Eur. J. Biochem. 129, 191^195.
[13] Vincent, M.F., Marangos, P.J., Gruber, H.E. and Van den
Berghe, G. (1991) Diabetes 40, 1259^1266.
[14] Bergmeyer, H.U. (1984) Methods of Enzymatic Analysis, 3rd
edn., Vol. 6, Verlag Chemie, Weinheim.
[15] Ha, J., Daniel, S., Broyles, S.S. and Kim, K.H. (1994) J. Biol.
Chem. 269, 22162^22168.
[16] Bontemps, F., Hue, L. and Hers, H.G. (1978) Biochem. J. 174,
603^611.
[17] Ponticos, M., Lu, Q.L., Morgan, J.E., Hardie, D.G., Partridge,
T.A. and Carling, D. (1998) EMBO J. 17, 1688^1699.
[18] Schmidt, H.D. (2001) Res. Exp. Med. 200, 107^124.
[19] Winder, W.W. and Hardie, D.G. (1996) Am. J. Physiol. 270,
E299^E304.
[20] Deprez, J., Bertrand, L., Alessi, D.R., Krause, U., Hue, L. and
Rider, M.H. (2000) Biochem. J. 347, 305^312.
[21] Deprez, J., Vertommen, D., Alessi, D.R., Hue, L. and Rider,
M.H. (1997) J. Biol. Chem. 272, 17269^17275.
[22] Wang, L., Wang, X. and Proud, C.G. (2000) Am. J. Physiol. 278,
H1056^H1068.
[23] Proud, C.G. (1996) Trends Biochem. Sci. 21, 181^185.
[24] Fujii, N., Hayashi, T., Hirshman, M.F., Smith, J.T., Habinowski,
S.A., Kaijser, L., Mu, J., Ljungqvist, O., Birnbaum, M.J., Wit-
ters, L.A., Thorell, A. and Goodyear, L.J. (2000) Biochem. Bio-
phys. Res. Commun. 273, 1150^1155.
[25] Till, M., Ouwens, M., Kessler, A. and Eckel, J. (2000) Biochem.
J. 346, 841^847.
[26] Lefebvre, V., Me¤chin, M.C., Louckx, M.P., Rider, M.H. and
Hue, L. (1996) J. Biol. Chem. 271, 22289^22292.
[27] Sakamoto, K., Hirshman, M.F., Aschenbach, W.G. and Good-
year, L.J. (2002) J. Biol. Chem. 277, 11910^11917.
[28] Dimmeler, S., Assmus, B., Hermann, C., Haendeler, J. and
Zeiher, A.M. (1998) Circ. Res. 83, 334^341.
[29] Doenst, T., Richwine, R.T., Bray, M.S., Goodwin, G.W., Fra-
zier, O.H. and Taegtmeyer, H. (1999) Ann. Thorac. Surg. 67,
1682^1688.
[30] Northcott, C.A., Poy, M.N., Najjar, S.M. and Watts, S.W.
(2002) Circ. Res. 91, 360^369.
[31] Matsui, T., Li, L., Wu, J.C., Cook, S.A., Nagoshi, T., Picard,
M.H., Liao, R. and Rosenzweig, A. (2002) J. Biol. Chem. 277,
22896^22901.
[32] Tian, R., Musi, N., D’Agostino, J., Hirshman, M.F. and Good-
year, L.J. (2001) Circulation 104, 1664^1669.
FEBS 26698 23-10-02
C. Beauloye et al./FEBS Letters 531 (2002) 324^328328
